期刊
TOXICOLOGY AND APPLIED PHARMACOLOGY
卷 289, 期 1, 页码 40-47出版社
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.taap.2015.08.022
关键词
Drug-induced steatohepatitis; Chemotherapy-associated steatohepatitis; Cationic amphiphilic drugs; Carnitine palmitoyltransferase-I; Mitochondrial toxicity
资金
- NIDDK NIH HHS [R01 DK081343, R56 DK090036] Funding Source: Medline
- NIEHS NIH HHS [T32 ES007148] Funding Source: Medline
- NIGMS NIH HHS [R01 GM104037] Funding Source: Medline
Drug-induced steatohepatitis is a rare form of liver injury known to be caused by only a handful of compounds. These compounds stimulate the development of steatohepatitis through their toxicity to hepatocyte mitochondria; inhibition of beta-oxidation, mitochondrial respiration, and/or oxidative phosphorylation. Other mechanisms discussed include the disruption of phospholipid metabolism in lysosomes, prevention of lipid egress from hepatocytes, targeting mitochondrial DNA and topoisomerase, decreasing intestinal barrier function, activation of the adenosine pathway, increasing fatty acid synthesis, and sequestration of coenzyme A. It has been found that the majority of compounds that induce steatohepatitis have cationic amphiphilic structures; a lipophilic ring structure with a side chain containing a cationic secondary or tertiary amine. Within the last decade, the ability of many chemotherapeutics to cause steatohepatitis has become more evident coining the term chemotherapy-associated steatohepatitis (CASH). The mechanisms behind drug-induced steatohepatitis are discussed with a focus on cationic amphiphilic drugs and chemotherapeutic agents. (C) 2015 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据